



4 July 2013

Dr Stephen Smith  
Division of Surgery  
John Hunter Hospital

Dear Dr Smith,

**Re: ALPHI Study: A double-blind randomised, placebo-controlled trial to assess the efficacy of Loperamide versus Placebo as postoperative prevention of high output ileostomy losses in patients with new loop ileostomy (13/06/19/3.04)**

**HNEHREC Reference No: 13/06/19/3.04**  
**NSW HREC Reference No: HREC/13/HNE/221**

Thank you for submitting the above protocol for single ethical review for a multi-centre study. This project was first considered by the Hunter New England Human Research Ethics Committee at its meeting held on **19 June 2013**. This Human Research Ethics Committee is constituted and operates in accordance with the National Health and Medical Research Council's *National Statement on Ethical Conduct in Human Research (2007)* (National Statement) and the *CPMP/ICH Note for Guidance on Good Clinical Practice*. Further, this Committee has been accredited by the NSW Department of Health as a lead HREC under the model for single ethical and scientific review. The Committee's Terms of Reference are available from the Hunter New England Local Health District website: [http://www.hnehealth.nsw.gov.au/Human\\_Research\\_Ethics](http://www.hnehealth.nsw.gov.au/Human_Research_Ethics).

I am pleased to advise that following acceptance under delegated authority of the requested clarifications and revised Protocol and Information Statement by Dr Nicole Gerrand Manager, Research Ethics & Governance, the Hunter New England Human Research Ethics Committee has granted ethical approval of the above project.

The following documentation has been reviewed and approved by the Hunter New England Human Research Ethics Committee:

- For the revised Clinical Trial Protocol (Version 6 dated 28 June 2013);
- For the revised Participant Information Statement and Consent Form (Version 1 dated 27 May 2013)

For the protocol: **A double-blind randomised, placebo-controlled trial to assess the efficacy of Loperamide versus Placebo as postoperative prevention of high output ileostomy losses in patients with new loop ileostomy [ALPHI Study Protocol No. JHGIS04 Version 6 dated 28 June 2013]**

Approval has been granted for this study to take place at the following sites:

- **John Hunter Hospital**
- **Newcastle Private Hospital**

**Hunter New England Research Ethics & Governance Unit**

(Locked Bag No 1)

(New Lambton NSW 2305)

Telephone (02) 49214 950 Facsimile (02) 49214 818

Email: [hnehrec@hnehealth.nsw.gov.au](mailto:hnehrec@hnehealth.nsw.gov.au)

[http://www.hnehealth.nsw.gov.au/research\\_ethics\\_and\\_governance\\_unit](http://www.hnehealth.nsw.gov.au/research_ethics_and_governance_unit)

Approval from the Hunter New England Human Research Ethics Committee for the above protocol is given for a maximum of 3 years from the date of this letter, after which a renewal application will be required if the protocol has not been completed.

The *National Statement on Ethical Conduct in Human Research (2007)*, which the Committee is obliged to adhere to, include the requirement that the committee monitors the research protocols it has approved. In order for the Committee to fulfil this function, it requires:

- A report of the progress of the above protocol be submitted at 12 monthly intervals. Your review date is **July 2014**. A proforma for the annual report will be sent two weeks prior to the due date.
- A final report must be submitted at the completion of the above protocol, that is, after data analysis has been completed and a final report compiled. A proforma for the final report will be sent two weeks prior to the due date.
- All variations or amendments to this protocol, including amendments to the Information Sheet and Consent Form, must be forwarded to and approved by the Hunter New England Human Research Ethics Committee prior to their implementation.
- The Principal Investigator will immediately report anything which might warrant review of ethical approval of the project in the specified format, including:
  - any serious or unexpected adverse events
    - Adverse events, however minor, must be recorded as observed by the Investigator or as volunteered by a participant in this protocol. Full details will be documented, whether or not the Investigator or his deputies considers the event to be related to the trial substance or procedure. These do not need to be reported to the Hunter New England Human Research Ethics Committee
    - Serious adverse events that occur during the study or within six months of completion of the trial at your site should be reported to the Manager, Research Ethics & Governance, of the Hunter New England Human Research Ethics Committee as soon as possible and at the latest within 72 hours.
    - All other safety reporting should be in accordance with the NHMRC's Safety Monitoring Position Statement – May 2009 available at [http://www.nhmrc.gov.au/health\\_ethics/hrecs/reference/files/090609\\_nhmrc\\_position\\_statement.pdf](http://www.nhmrc.gov.au/health_ethics/hrecs/reference/files/090609_nhmrc_position_statement.pdf)
    - Serious adverse events are defined as:
      - Causing death, life threatening or serious disability.
      - Cause or prolong hospitalisation.
      - Overdoses, cancers, congenital abnormalities whether judged to be caused by the investigational agent or new procedure or not.
  - Unforeseen events that might affect continued ethical acceptability of the project.

**Hunter New England Research Ethics & Governance Unit**

(Locked Bag No 1)

(New Lambton NSW 2305)

Telephone (02) 49214 950 Facsimile (02) 49214 818

Email: [hnehrec@hnehealth.nsw.gov.au](mailto:hnehrec@hnehealth.nsw.gov.au)

[http://www.hnehealth.nsw.gov.au/research\\_ethics\\_and\\_governance\\_unit](http://www.hnehealth.nsw.gov.au/research_ethics_and_governance_unit)

- If for some reason the above protocol does not commence (for example it does not receive funding); is suspended or discontinued, please inform Dr Nicole Gerrand, as soon as possible.

**You are reminded that this letter constitutes ethical approval only. You must not commence this research project at a site until separate authorisation from the Chief Executive or delegate of that site has been obtained.**

A copy of this letter must be forwarded to all site investigators for submission to the relevant Research Governance Officer.

Should you have any concerns or questions about your research, please contact Dr Gerrand as per the details at the bottom of the page. The Hunter New England Human Research Ethics Committee wishes you every success in your research.

Please quote **13/06/19/3.04** in all correspondence.

The Hunter New England Human Research Ethics Committee wishes you every success in your research.

Yours faithfully



For: Professor M Parsons  
Chair  
Hunter New England Human Research Ethics Committee

**Hunter New England Research Ethics & Governance Unit**

(Locked Bag No 1)

(New Lambton NSW 2305)

Telephone (02) 49214 950 Facsimile (02) 49214 818

Email: [hnehrec@hnehealth.nsw.gov.au](mailto:hnehrec@hnehealth.nsw.gov.au)

[http://www.hnehealth.nsw.gov.au/research\\_ethics\\_and\\_governance\\_unit](http://www.hnehealth.nsw.gov.au/research_ethics_and_governance_unit)